Gene polymorphic markers for predicting angiotensin converting enzyme (ACE) activity, risk of strokes, and blood pressure responsivenss to ACE inhibitors
Docket Number:12A-990315
Inventor:Wen-Harn Pan, Chia-Min Chung, Jaw-Wen Chen
IP Status:TW I392741
Abstract:
We have found that the ACE activity is significantly associated with genetic variations at the ACE, and ABO loci in hypertensive and in normotensive subjects by conducting a two-stage genome-wide association study. Inasmuch as we know, ours is the first attempt to have demonstrated that ABO gene may play a vital role in modulatting the ACE activity. These findings explain some of controversial results regarding the relations between ACE activity (genotypes), blood pressure regulation and cardiovascular diseases. We further demonstrated a potential differential blood pressure response to ACEI in subjects with varied numbers of ACE activity–raising alleles. Finally, we found that ACE activity–raising alleles increased the risk of stroke in a large cohort study.
Fields of Application:
Our findings can be applied to assist selecting hypertensive medication, e.g. directing ACEI to those with genetic susceptibility to high ACE activity. ACE activity, is implicated in pharmaco-genomics and may potentially lead to changing the customary trial-and-error practice in hypertension treatment. ACE activity–raising score can also be applied to screen high risk individuals for stroke.
Advantages when compared to the existing technologies:
No pharmacogenetic association between ACE I/D genotype and blood pressure response was identified in previous large-scale clinical trial studies. Our finding reveals novel ABO gene which plays a vital role in modulating the ACE activity. We determined ACE activity-raising genetic scores for each individual by combining genotype information from ACE gene and ABO gene, which is a better predictor of the blood pressure response to the ACEI and stroke risk.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
